Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)

Stroke

Volumn 39, Issue 1, 2008, Pages 87-99

  Adams Jr , Harold P ^a   Effron, Mark B ^b   Torner, James ^c   Dávalos, Antoni ^d   Frayne, Judith ^e   Teal, Philip ^f   Leclerc, Jacques ^b   Oemar, Barry ^g   Padgett, Lakshmi ^g   Barnathan, Elliot S ^g   Hacke, Werner ^h  

^a UNIVERSITY OF IOWA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g CENTOCOR INC   (United States)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Abciximab; Acute stroke treatment; Hemorrhagic transformation; Ischemic stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; PLACEBO; ANTICOAGULANT AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY TREATMENT; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RESPIRATORY TRACT DISEASE; SYMPTOM; TIME; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CONVALESCENCE; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; STROKE; WAKEFULNESS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CEREBRAL HEMORRHAGE; DOUBLE-BLIND METHOD; EMERGENCY TREATMENT; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TREATMENT OUTCOME; WAKEFULNESS;

EID: 38149053126     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.476648     Document Type: Article

References (23)

1. Zhang ZG, Chopp M, Goussev A, Lu D, Morris D, Tsang W, Powers C, Ho KL. Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci. 1999;19:10898-10907.
2. Zhang ZG, Zhang L, Tsang W, Goussev A, Powers C, Ho KL, Morris D, Smyth SS, Coller BS, Chopp M. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res. 2001;912:181-194.
3. Zhang L, Zhang Z, Zhang C, Zhang RL, Chopp M. Intravenous administration of a GPIIb/IIIa receptor antagonist extends teh therapeutic window of intra-arterial tenecteplase-tissue-tissue plasminogen activator in a rat stroke model. Stroke. 2004;35:2890-2895.
4. Zhang L, Zhang ZG, Zhang R, Morris D, Lu M, Coller BS, Chopp M. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen administration in a rat model of embolic stroke. Circulation. 2003;107:2837-2843.
5. Morris DC, Silver B, Mitsias P, Lewandowski C, Patel S, Daley S, Zhang ZG, Lu M. Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab. Acad Emerg Med. 2003;10:1396-1399.
6. Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, Chopp M. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke. 2001;32:2635-2640.
7. Qureshi AI, Suri FK, Khan J, Fessler RD, Guterman LR, Hopkins LN. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience. Neurosurgery. 2000;46:1316-1325.
8. Qureshi AI, Suri MF, Ali Z, Kim SH, Lanzino G, Fessler RD. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery. 2002;50:466-473.
9. lee KY, Heo JH, Lee SI, Yoon WB. Rescue treatment with abciximab in acute ischemic stroke. Neurology. 2001;56:1585-1587.
10. Ho DS, Wang Y, Chui M, Ho SL, Cheung RT. Intracarotid abciximab injection to abort impending ischemic stroke during carotid angioplasty. Cerebrovasc Dis. 2001;11:300-304.
11. Mitsias PD, Lu M, Morris D, Silver B, Lewandowski C, Papamitsakis NI, Khaligi MM, Ebadian HB, Zhao Q, Soltanian-Zadeh H, Daley S, Hearshen D, Ewing JR, Patel SC, Chopp M. Treatment of acute supratentorial ischemic stroke with abciximab is safe and may result in early neurological improvement: A Preliminary Report. Cerebrovasc Dis. 2004;18:249-250.
12. Mandava P, Lick SD, Rahman MA, Langsjoen H, Reddy KV, Nelson J, Kent TA. Initial saety experience of abciximab and heparin for acute ischemic stroke. Cerebrovasc Dis. 2005;19:276-278.
13. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke. 2000;31:601-609.
14. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke. Results of a randomized phase 2 trial. Stroke. 2005;36:880-890.
15. Adams HP Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis. 2004;18:124-129.
16. Serena J, Davalos A, Segura T, MOstacero E, Castillo J. Stroke on awakening: looking for a more rational management. Cerebrovasc Dis. 2003;16:128-133.
17. Fink JN, Kumar S, Horkan C, Linfante I, Selim MH, Caplan LR, Schlaug G. The stroke patient who woke up: clinical and radiological features, including diffusion and perfusion MRI. Stroke. 2002;33:988-993.
18. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103-115.
19. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
20. Todo K, Moriwaki H, Saito K, Tanaka M, Oe H, Naritomi H. Early CT findings in unknown-onset and wake-up strokes. Cerebrovasc Dis. 2006;21:367-371.
21. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for Acute Ischemic Stroke. N Engl J Med. 2006;354:588-600.
22. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
23. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.